Targeted cancer drugs known as CDK4/6 inhibitors have improved outcomes for patients with advanced or metastatic HR+/HER2- breast cancer, but many patients still eventually relapse and become resistant to therapy. New research co-headed by a Fox Chase Cancer Center scientist helps explain why—and offers three strategies for making treatment more effective.